GBI Research Release: HIV Generics Take Over the Antivirals Market
Published: Jun 29, 2012
The new report* states that an increase in the patient population and reforms in government policies will work together to encourage the rise of generic pharmaceutical powers.
Government policies include the need for prior authorization in order to dispense branded drugs that have generic alternatives, while further incentives are available from Pharmacy Benefit Managers (PBM) for dispensing generic drugs. These kinds of regulatory changes and financial benefits could act as significant drivers of the market during the forecast period.
While it is estimated that, in 2010, generics accounted for 18.9% of the market share in the global antivirals market, this market share is forecast to grow to reach 29.2% by 2018. This is largely due to a series of patent expiries expected to hit the antiviral market, which will act to raise the value of generic antiviral drugs to over $9 billion by 2018.
Generics in the HIV market in particular accounted for an estimated majority market share of 46% in the total generic antivirals market during 2010. HIV generics are expected to create a boom in the market, due to a loss of patent exclusivity for key antiviral drugs.
The generic market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. However, many major patent expiries are expected during the forecast period, including Sustiva (efavirenz) and Kaletra (lopinavir + ritonavir) in 2013, Prezista (darunavir ethanolate) in 2014, and major Nucleoside Reverse Transcriptase Inhibitors (NRTIs) such as Trizivir (abacavir sulphate/lamivudine/zidovudine), Epzicom (lamivudine and abacavir) and Emtriva (emtricitabine) in 2016.
By 2018, billions of dollars’ worth of industry revenue will be lost from the expiry of these brand name products, and the race will be on for generics manufacturers to create new superstar drugs to make the most of this unmet need in the market. Generics within the antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018.
In December 2011, Teva launched generic Combivir in the US market as a combination tablet containing lamivudine and zidovudine, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Combivir had annual sales of approximately $556m in 2010, based on the annual report.
*Generics in the Antivirals Market to 2018 – Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
This report describes generic market in antiviral therapeutics, and covers antiviral therapeutics including HIV therapeutics, Hepatitis therapeutics, Herpes therapeutics, CMV therapeutics and Influenza therapeutics.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
-ABOUT GBI RESEARCH-
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at firstname.lastname@example.org